University System of Maryland

David B Snyder

Vikram N Vakharia

Stephanie A Mengel-Whersat

Sammy L Gorham

Dolores P Lana

Warren W Marquardt

Heinrich D Luetticken

Two monoclonal antibodies which neutralize all infectious bursal disease viruses are employed in the preparation of infectious bursal disease vaccines. A panel of monoclonal antibodies can be used to characterize the infectious bursal disease virus strains present, according to neutralization site characteristics.

Monoclonal antibodies for infectious bursal disease, vaccines and assays for use therewith

Chimeric cDNA for the expression of immunogenic polypeptides include the genetic epitopic determinants for a base infectious bursal disease virus strain and at least one other infectious bursal disease virus strain. The genetic epitopic determinants encode amino acids or amino acid sequences which define epitopes bound to by previously established monoclonal antibodies. The immunogens expressed by the cDNA may be employed to provide a vaccine against a plurality of IBDV strains. The epitopic determinant of IBDV lethal strains has been detected, and an immunogen for conferring immunity with respect thereto is disclosed. Similarly, a monoclonal antibody specific for IBDV lethal strains is identified, and a vaccine for passive immunization therewith is also disclosed. Immunogens exhibiting conformational epitopes, in the form of virus-like particles, are effective in the preparation of vaccines.

Chimeric infectious bursal disease virus cDNA clones, expression

Chimeric cDNA for the expression of immunogenic polypeptides include the genetic epitopic determinants for a base infectious bursal disease virus strain and at least one other infectious bursal disease virus strain. The genetic epitopic determinants encode amino acids or amino acid sequences which define epitopes bound to by previously established monoclonal antibodies. The immunogens expressed by the cDNA may be employed to provide a vaccine against a plurality of IBDV strains. The epitopic determinant of IBDV lethal strains has been detected, and an immunogen for conferring immunity is disclosed. Similarly, a monoclonal antibody specific for IBDV lethal strains is identified, and a vaccine for passive immunization is also disclosed. Immunogens exhibiting conformational epitopes, in the form of virus-like particles, are effective in the preparation of vaccines.

Chimeric infectious bursal disease virus CDNA clones, expression

Live, attenuated Delaware infectious bursal disease viruses are screened for effectiveness by a monoclonal antibody specific for said Delaware strain. Those which are not bound by the antibody are not or may not be as effective in conferring protection against homologous wild type infectious bursal disease infection. Currently available live, attenuated vaccines do not include a virus having the binding site specified. A monoclonal antibody specific for the Delaware strain also provides a vaccine for passive immunization.

Attenuated, live vaccine for Delaware strain IBDV

A new virus not neutralized or bound by monoclonal antibodies which bind and neutralize all IBD vaccines of current art, and capable of inducing infectious bursal disease in poultry is identified, in essentially pure form. A test kit, and assay for the presence of the virus is disclosed, together with the vaccine incorporating the virus.

Novel infectious bursal disease virus

Monoclonal antibodies effective in preventing infectious bursal disease in chickens, by neutralizing one or more virus strains thereof, have been isolated and obtained from deposited hybridomas. Vaccination of an entire poultry population with a vaccine prepared from these monoclonal antibodies gives a uniform level of protection against all strains of infectious bursal disease tested. The monoclonal antibodies were effective in inducing priming for an active anti-viral response in a heterologous host.

Monoclonal antibody which neutralizes multiple strains of infectious

A method for determining the level of infectious bursal disease virus IBDV neutralizing antibody in poultry comprising a labeled monoclonal antibody R63 having the IBDV neutralizing capability of the monoclonal antibody expressed by hybridoma cell line ATCC HB-9490. Monoclonal antibody R63 is specific to all known IBDV strains and serotypes and competes only with itself and other antibodies recognizing the same neutralizing epitope present in poultry sera. In a competition assay, the increase in unbound labeled monoclonal antibody is an indication of the level of IBDV neutralizing antibody present in poultry sera.

Growing community of inventors

Bowie, MD, United States of America

David B Snyder